The role of hyperthermia in combined treatment in the management of soft tissue sarcoma
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2006-07-01 / Curr Oncol Rep 2006 Jul;8(4):305-9Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy
/in Glioblastoma, International Publications /von 2006-07-01 / J. Neurosurg. 2006 Jul;105(1):41-50Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice
/in Glioblastoma, International Publications /von 2006-07-01 / Neurol. Res. 2006 Jul;28(5):527-31Induction of alpha-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells
/in Hepatocellular Carcinoma, International Publications /von 2006-06-30 / Cell. Immunol. 2006 Feb;239(2):144-50Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo
/in International Publications, Pancreatic Cancer /von 2006-06-13 / Int. Immunol. 2006 Aug;18(8):1279-83Temperature data analysis for 22 patients with advanced cervical carcinoma treated in Rotterdam using radiotherapy, hyperthermia and chemotherapy: a reference point is needed
/in Cervical Cancer, International Publications /von 2006-06-01 / Int J Hyperthermia 2006 Jun;22(4):353-63Restoration in vitro of impaired T-cell responses in patients with chronic hepatitis B by autologous dendritic cells loaded with hepatitis B virus proteins (R2)
/in Chronic Virus Hepatitis, International Publications /von 2006-06-01 / J. Gastroenterol. Hepatol. 2006 Jun;21(6):970-6Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma
/in Hepatocellular Carcinoma, International Publications /von 2006-06-01 / Cell. Mol. Immunol. 2006 Jun;3(3):197-203Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial
/in HIV/AIDS, International Publications /von 2006-06-01 / J. Med. Virol. 2006 Jun;78(6):711-8
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de